Pre-Made Interferon Alfa Biosimilar, Recombinant Protein targeting IFNAR1: Recombinant therapeutic protein targeting AVP/IFN-alpha-REC/IFNAR/IFNBR/IFRC for drug discovery and mechanism of action (MOA) research

Pre-Made Interferon Alfa Biosimilar, Recombinant Protein targeting IFNAR1: Recombinant therapeutic protein targeting AVP/IFN-alpha-REC/IFNAR/IFNBR/IFRC is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Interferon alfa (INN) or HuIFN-alpha-Le, trade name Multiferon, is a pharmaceutical drug composed of natural interferon alpha (IFN-α), obtained from the leukocyte fraction of human blood following induction with Sendai virus. Interferon alfa contains several naturally occurring IFN-α subtypes and is purified by affinity chromatography. Although the pharmaceutical product is often simply called "interferon alpha" or "IFN-α" like its endogenous counterpart, the product's International nonproprietary name (INN) is interferon alfa (the spelling of 'alfa' with 'f' reflects INN naming conventions).

Interferon alfa is an immunomodulator used to treat hepatitis B and C as well as certain types of cancer including cutaneous T-cell lymphoma and renal cell carcinoma.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-INN-871-1mg	1mg	3090
GMP-Bios-INN-871-10mg	10mg	Inquiry
GMP-Bios-INN-871-100mg	100mg	Inquiry
GMP-Bios-INN-871-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Interferon Alfa Biosimilar, Recombinant Protein targeting IFNAR1: Recombinant therapeutic protein targeting AVP/IFN-alpha-REC/IFNAR/IFNBR/IFRC
INN Name	Interferon Alfa
Target	IFNAR1
Format	Recombinant Protein
Derivation	0
Species Reactivity	human
CH1 Isotype	IFNA2 (interferon alpha 2) *a (K56,H57) 24-188
VD LC	IFNA2 (interferon alpha 2) *a (K56,H57) 24-188
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
Companies	Roche, F. Hoffmann-La Roche Ltd. (Basel Switzerland)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech	0